NCT00258245View on ClinicalTrials.gov

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DIETARY_SUPPLEMENT

ascorbic acid

Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11

DRUG

arsenic trioxide

Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11

DRUG

bortezomib

Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11

DRUG

dexamethasone

Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11

DRUG

thalidomide

Thalidomide (Thalomid) - 50 mg/day by mouth (PO)

DRUG

Aspirin

Aspirin - 325 mg by mouth (PO) every day

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00258245 - Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | Biotech Hunter | Biotech Hunter